Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines
Top Cited Papers
Open Access
- 1 October 2012
- journal article
- practice guideline
- Published by Elsevier BV in Annals Of Oncology
- Vol. 23 (suppl_7), vii155-vii166
- https://doi.org/10.1093/annonc/mds293
Abstract
Cardiovascular (CV) toxicity is a potential short- or long-term complication of various anticancer therapies. Some drugs, such as anthracyclines or other biological agents, have been implicated in causing potentially irreversible clinically important cardiac dysfunction. Although targeted therapies are considered less toxic and better tolerated by patients compared with classic chemotherapy agents, rare but serious complications have been described, and longer follow-up is needed to determine the exact profile and outcomes of related cardiac side-effects. Some of these side-effects are irreversible, leading to progressive CV disease, and some others induce reversible dysfunction with no long-term cardiac damage to the patient. Assessment of the prevalence, type and severity of cardiac toxicity caused by various cancer treatments is a breakthrough topic for patient management. Guidelines for preventing, monitoring and treating cardiac side-effects are a major medical need. Efforts are needed to promote strategies for cardiac risk prevention, detection and management, avoiding unintended consequences that can impede development, regulatory approval and patient access to novel therapy. These new ESMO Clinical Practice Guidelines are the result of a multidisciplinary cardio-oncology review of current evidence with the ultimate goal of providing strict criteria-based recommendations on CV risk prevention, assessment, monitoring and management during anticancer treatment.Keywords
This publication has 46 references indexed in Scilit:
- Adjuvant Trastuzumab in HER2-Positive Breast CancerNew England Journal of Medicine, 2011
- Anthracycline-Induced CardiomyopathyJournal of the American College of Cardiology, 2010
- Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoringBritish Journal of Cancer, 2009
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerNew England Journal of Medicine, 2007
- Drug-induced QTc interval prolongation: A proposal towards an efficient and safe anticancer drug developmentEuropean Journal Of Cancer, 2007
- Mechanisms of adverse effects of anti-VEGF therapy for cancerBritish Journal of Cancer, 2007
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Adjuvant Docetaxel for Node-Positive Breast CancerNew England Journal of Medicine, 2005
- Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose ChemotherapyCell Metabolism, 2004
- Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapyJournal of the American College of Cardiology, 2000